Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $66.00 Average PT from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $66.00.

A number of analysts have recently commented on the company. Guggenheim boosted their price target on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Friday, March 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Wednesday, April 17th.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP grew its position in shares of Celldex Therapeutics by 5.9% in the third quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock valued at $149,484,000 after purchasing an additional 300,406 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Celldex Therapeutics by 192.0% in the third quarter. GSA Capital Partners LLP now owns 44,716 shares of the biopharmaceutical company’s stock valued at $1,231,000 after purchasing an additional 29,404 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Celldex Therapeutics in the fourth quarter valued at approximately $994,000. SG Americas Securities LLC grew its position in shares of Celldex Therapeutics by 1,481.7% in the third quarter. SG Americas Securities LLC now owns 78,011 shares of the biopharmaceutical company’s stock valued at $2,147,000 after purchasing an additional 73,079 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Celldex Therapeutics by 3.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 361,547 shares of the biopharmaceutical company’s stock valued at $9,950,000 after purchasing an additional 10,818 shares during the last quarter.

Celldex Therapeutics Trading Down 2.8 %

CLDX stock opened at $37.77 on Wednesday. The business’s 50-day moving average price is $42.11 and its two-hundred day moving average price is $36.08. The firm has a market cap of $2.11 billion, a PE ratio of -12.98 and a beta of 1.50. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.19. The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. On average, analysts forecast that Celldex Therapeutics will post -2.85 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.